These data suggest that 2-HG acts as an agonist of PHDs thereby reducing HIF-1α levels and promoting tumourigenesis, which is concordant with the repression of HIF-1α targets in IDH-mutant, relative to wild-type, glioma patients [76]. This evidence concerns the gene IDH1 and central nervous system cancer.